PROstate CAncer Real World Evidence Registry: RECURRENT AND METASTATIC PROSTATE CANCER - PROCARE

roTrials GmbH0 个研究点目标入组 5,000 人开始时间: 2024年1月15日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Adult prostate cancer patients (age =18 years).
•Diagnosis at time of study inclusion
•Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof)
•Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or
•Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or
•Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)
•Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, … line).
•For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient.
•Patients, who are able and willing to sign the informed consent form

•Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician

发起方

roTrials GmbH